地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172431432
传真:18327026838
邮箱:sales@amyjet.com

艾美捷科技代理Ambinter品牌。
Ambinter隶属于Greenpharma品牌,是重要的药物发现专用化合物供应商。Ambinter拥有超过25年的合成经验,其数据库包含超过4600万种用于高通量筛选的化合物、构建模块以及各种片段和天然产物。Ambinter提供具有高度生物活性的复杂和稀有化学品。在Greenpharma的支持下,Ambinter还提供包括定制合成、化学信息学和分子建模、分析化学、研发项目管理在内的服务项目。
< " data-original="http://pharna.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Ambinter品牌"> 艾美捷科技代理Ambinter品牌
艾美捷科技代理Epredia品牌。
Epredia是一家全球性公司,致力于实现精准癌症诊断,Epredia的产品组合代表了整个组织学工作流程,从标本采集到处理,从切片到染色,从成像到存档。Epredia由Shandon、Microm、Menzel Gläser和Richard-Allan Scientific等品牌组成,拥有广泛的解决方案,这些解决方案已经并将继续改变解剖病理学市场。
Epredia的解决方案包括:
(1)组织处理和包埋解决方案:随着新的工作环境和人员配备挑战的出现,了解组织处理试剂如何节省时间并提高处理组织的质量至关重要。
(2)标签和跟踪解决方案:PrintMate AS™盒式打印机和SlideMate幻灯片打印机系列,减少因标签错误而出错的机会,并通过自动化的方式标记和跟踪实验室样本和幻灯片来简化工作流程。
(3)组合解决方案:Epredia一直在寻找简化工作流程的方法,同时增强结果。
(4)存档解决方案:存档是实验室中确保整个组织学工作流程中样本安全的重要过程。
< " data-original="http://pharna.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Epredia品牌"> 艾美捷科技代理Epredia品牌
<艾美捷科技代理Separopore品牌全系列产品
Separopore是美国生物技术公司bioWORLD旗下的核心色谱品牌,Separopore专攻多孔琼脂糖微球色谱介质,主打 "高分辨率分离纯化" 技术,覆盖亲和色谱、离子交换、分子筛等应用场景。产品广泛应用于单克隆抗体/重组蛋白纯化、病毒载体(AAV, 慢病毒)捕获,疫苗抗原精制以及核酸/酶工程等领域。

▍Separopore产品线
| 类型 | 应用场景 | 代表产品 |
| 亲和色谱介质 | 抗体/融合蛋白纯化 | Separopore® Protein A/G |
| 金属螯合介质 | 组氨酸标签蛋白捕获 | Separopore® Ni-NTA |
| 离子交换介质 | 核酸/酶纯化 | Q/S SP/CM 系列 |
| 疏水层析介质 | 膜蛋白/病毒纯化 | Phenyl/Octyl 系列 |
| 分子筛介质 | 脱盐/缓冲液置换 | Separopore® SEC Beads |
Separopore的材料特征:
①基质成分:交联 4% 或 6% 琼脂糖(agarose),形成刚性多孔珠状结构
②物理优势:高孔隙率 & 均一粒径(45-165 μm 可选);耐压性强(可承受 >0.3 MPa 操作压力);低非特异性吸附
③表面修饰:可定制化偶联 Protein A/G、镍离子、抗体、凝集素 等配体
▍Separopore部分产品列表
| 品名 | 规格 | 货号 |
| AMP Separopore® 4B-CL | 1 g;3 g | 20181079 |
| Anti-DYKDDDDK (FLAG) Red Separopore® 4B Microbeads viewIP™ | 1 mL | 20181114 |
| Goat Anti-Human IgG Separopore® 4B-CL | 5 mL | 20181134 |
| L-Lysine Separopore® 4B-CL | 5 mL;10 mL;25 mL | 20181070 |
| L-Methionine Separopore® 6B-CL | 10 mL;25 mL | 20181160 |
| L-Phenylalanine Separopore® 4B-CL | 5 mL;10 mL;25 mL | 20181071 |
| L-Proline Separopore® 6B-CL | 10 mL;25 mL | 20181161 |
| L-Serine Separopore® 6B-CL | 10 mL;25 mL | 20181162 |
| L-Threonine Separopore® 6B-CL | 10 mL;25 mL | 20181163 |
| L-Valine Separopore® 6B-CL | 10 mL;25 mL | 20181164 |
| Lens culinaris Lectin (LCA/LCH) - Separopore® 4B OnePASS™ Column | 3.25 mL;8 mL | 30330004-1 |
| Lycopersicon esculentum Lectin (LEL/LEA) - Separopore® 4B OnePASS™ Column | 3.25 mL;6 mL | 30330005-1 |
| Maackia amurensis Lectin (MAA/MAL I) - Separopore® 4B OnePASS™ Column | 3 mL | 20120088-1 |
| Maclura pomifera Lectin (MPL/MPA) - Separopore® 4B OnePASS™ Column | 3 mL | 21511124-1 |
| MagneZoom™ (Paramagnetic Beads) Control | 1 mL;2 mL | 20162011-2 |
| Maltose Separopore® 4B (Epoxy-Coupled) | 10 mL;25 mL;50 mL;100 mL | 20181175 |
| Mannose Separopore® 4B-CL (Divinyl Sulfone-Coupled) | 10 mL;25 mL;50 mL;100 mL | 20181019 |
| Mannose Separopore® 4B-CL (Epoxy-Coupled) | 10 mL;25 mL;50 mL;100 mL | 20111005 |
| Melibiose Separopore® 4B (Divinyl Sulfone-Coupled) | 10 mL;25 mL | 20181178 |
| Melibiose Separopore® 4B (Epoxy-Coupled) | 10 mL;25 mL | 20181148-1 |
| N-Acetyl-D-Galactosamine Separopore® 4B-CL | 2 mL;5 mL;10 mL | 20181021 |
| N-Acetyl-D-Glucosamine (GlcNAc) Separopore® 4B-CL | 2 mL;5 mL;10 mL | 20181022 |
| NAADP Separopore® 4B-CL | 2 g | 20181122 |
| NAADP Separopore® 4B-CL (Carboxyl-Linked) | 2 g | 20181123 |
| Nickel Red Separopore® 4B Microbeads viewIP™ | 1 mL | 20181117 |
| Phaseolus vulgaris Lectin (PHA-E) - Separopore® 4B OnePASS™ Column | 3.25 mL;6 mL | 30330023-1 |
| Phaseolus vulgaris Lectin (PHA-E+L) - Separopore® 4B OnePASS™ Column | 3.25 mL;6 mL | 30330027-1 |
| Phaseolus vulgaris Lectin (PHA-L) - Separopore® 4B OnePASS™ Column | 3.25 mL;6 mL | 30330036-1 |
| Pisum sativum Lectin (PSA/PSL) - Separopore® 4B OnePASS™ Column | 3 mL | 21511137-1 |

艾美捷科技代理Rigaku Reagents品牌。
Rigaku Reagents 是 Rigaku 集团旗下的一家子公司,专注于为X射线晶体学领域提供高质量的化学试剂和工具。Rigaku 集团是全球知名的科学仪器制造商,尤其在X射线分析技术领域具有领先地位。Rigaku Reagents 的主要目标是支持科学家在蛋白质晶体学、材料科学和其他相关领域的研究,提供用于晶体生长、样品制备和分析的高质量试剂和耗材。热门产品包括:Wizard Classic/Wizard Cryo 系列蛋白结晶筛选试剂盒,结晶板,结晶工具,和 PEG3350、PEG6000、PEG8000 等试剂。主要产品类别为:
(1)晶体生长试剂:Rigaku Reagents 提供多种用于蛋白质和小分子晶体生长的试剂,包括结晶筛选试剂盒、缓冲液、沉淀剂和添加剂。这些试剂经过严格的质量控制,确保实验的可重复性和可靠性。
(2)结晶筛选试剂盒:公司提供多种结晶筛选试剂盒,如 Crystal Screen、Index Screen 和 SaltRx Screen,适用于不同类型的晶体生长实验。这些试剂盒设计科学,能够显著提高晶体生长的成功率。
(3)蛋白质结晶工具:提供用于蛋白质结晶的耗材和设备,如结晶板、密封膜和样品支架。这些工具与 Rigaku 的X射线衍射仪兼容,支持从晶体生长到数据分析的全流程。
(4)小分子结晶试剂:为小分子晶体学研究提供高质量的试剂和工具,支持药物开发、材料科学等领域的研究。
<<< " data-original="http://pharna.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Rigaku Reagents品牌"> 艾美捷科技代理Rigaku Reagents品牌

艾美捷科技有限公司代理Complement Technology全系列产品。
Complement Technology公司致力于为生物医学研究提供最高质量的补体试剂。Complement Tech的研发人员在补体相关试剂领域拥有80多年的丰富经验,是补体试剂的原始制造商。
Complement Technology公司的主要产品包括:
| Purified Proteins | |||
| 产品名称 | 货号 | mg/ml | µg/vial |
| C1 (Pure) | A098 | 0.2 | 200 |
| C1q | A099 | 1 | 1000 |
| C1q (40% Glycerol) | A100 | 1 | 1000 |
| C1r Proenzyme | A101 | 0.5 | 100 |
| C1r Enzyme | A102 | 1 | 250 |
| C1s Proenzyme | A103 | 1 | 250 |
| C1s Enzyme | A104 | 1 | 250 |
| C1 Esterase Inhibitor | A140 | 1 | 1000 |
| C1s-C1INH Complex *(NEW)* | C1040 | 0.5 | 50 |
| C2 | A112 | 0.5 | 50 |
| C3 | A113 | 1 | 250 |
| C3 (concentrated) | A113c | 5 | 1000 |
| C3a | A118 | 0.5 | 50 |
| C3a desArg | A119 | 0.5 | 50 |
| C3b | A114 | 1 | 250 |
| iC3b | A115 | 1 | 250 |
| C3c | A116 | 1 | 250 |
| C3d | A117 | 1 | 100 |
| C4 | A105 | 1 | 250 |
| C4 (concentrated) | A105c | 4 | 1000 |
| C4a | A106 | 0.5 | 50 |
| C4a desArg | A107 | 0.5 | 50 |
| C4b | A108 | 1 | 250 |
| C4b Binding Protein | A109 | 1 | 250 |
| C5 | A120 | 1 | 250 |
| C5a | A144 | 0.5 | 30 |
| C5a (300) | A144(300) | 0.5 | 300 |
| C5a desArg | A145 | 0.5 | 50 |
| C5b,6 | A122 | 0.2 | 50 |
| C6 | A123 | 1 | 250 |
| C7 | A124 | 1 | 250 |
| C8 | A125 | 1 | 250 |
| C9 | A126 | 1 | 250 |
| SC5b-9 Complex | A127 | 1 | 100 |
| Factor B | A135 | 1 | 250 |
| Factor D | A136 | 0.1 | 25 |
| Factor H | A137 | 1 | 250 |
| Factor H (conc.) | A137c | 10 | 10000 |
| Factor I | A138 | 1 | 100 |
| Factor P (Properdin) | A139 | 1 | 100 |
| Cobra Venom Factor (USA Only) | A150 | 1 | 1000 |
| Factor Ba | A154 | 1 | 100 |
| Factor Bb | A155 | 1 | 250 |
| Animal Proteins | |||
| 产品名称 | 货号 | mg/ml | µg/vial |
| Cyno C3 (USA Only) | CY113 | 1 | 100 |
| Cyno C3b (USA Only) | CY114 | 1 | 100 |
| Mouse C1q | M099 | 1 | 100 |
| Mouse C3 | M113 | 1 | 100 |
| Mouse C3b | M114 | 1 | 100 |
| Rat C1q | R099 | 1 | 100 |
| See Polyclonal Antisera page for Anti-Mouse C3 | M213 | - | - |
| Anaphylatoxin | |||
| 产品名称 | 货号 | mg/ml | µg/vial |
| C3a | A118 | 0.5 | 50 |
| C3a desArg | A119 | 0.5 | 50 |
| C4a | A106 | 0.5 | 50 |
| C4a desArg | A107 | 0.5 | 50 |
| C5a | A144 | 0.5 | 30 |
| C5a desArg | A145 | 0.5 | 50 |
| C5a (300) | A144(300) | 0.5 | 300 |
| Complement Assay Reagents | |||
| 产品名称 | 货号 | 体积 | |
| GVBo (without Ca and Mg) - 250ml | B103 | 250ml | |
| GVBo (without Ca and Mg) - 1L | B101 | 1 Liter | |
| GVB++ (with Ca and Mg) - 250ml | B102 | 250ml | |
| GVB++ (with Ca and Mg) - 1L | B100 | 1 Liter | |
| GVBE (with EDTA) - 250ml | B104 | 250ml | |
| GVBE (with EDTA) - 1L | B105 | 1 Liter | |
| SGVB++ (low ionic strength w/Sucrose, Ca and Mg) - 250ml | B110 | 250ml | |
| SGVB++(low ionic strength w/Sucrose, Ca and Mg) - 1L | B111 | 1 Liter | |
| VBS++ (with Ca and Mg) - 250ml | B112 | 250ml | |
| VBS++ (with Ca and Mg) - 1L | B113 | 1 Liter | |
| EA (Ab-sensitized sheep E) - 5ml | B200 | 5ml @ 5x10⁸/ml | |
| EA (Ab-sensitized sheep E) - 10ml | B201 | 10ml @ 5x10⁸/ml | |
| EA (Ab-sensitized sheep E) - 20ml | B202 | 20ml @ 5x10⁸/ml | |
| Es (sheep E) | B210 | 20ml @ 5x10⁸/ml | |
| Er (rabbit E) - 5ml | B300 | 5ml @ 5x10⁸ml | |
| Er (rabbit E) - 10ml | B301 | 5ml @ 5x10⁸/ml | |
| Er (rabbit E) - 20ml | B302 | 20ml @ 5x10⁸/ml | |
| Zymosan (preactivated) | B400 | 10ml @ 1x10⁹/ml | |
| MgEGTA | B106 | 10ml @ 0.1M | |
| MCAR | B250 | 1.0 ml | |
| Hemolysin | Hemolysin | 2.0 ml | |
" data-original="http://pharna.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Complement Technology"> Complement Technology

艾美捷科技代理SICGEN Antibodies品牌全系列抗体产品。
SICGEN Antibodies是一家专注于研发、生产和销售高质量抗体的生物技术公司,总部位于葡萄牙。SICGEN Antibodies公司开发了针对多种靶标的抗体,涵盖蛋白质、细胞标记物、信号通路分子等,被广泛应用于免疫学、神经科学、癌症研究、干细胞研究和诊断领域。SICGEN Antibodies主要产品类别包括:
(1)一抗(Primary Antibodies)
蛋白质研究抗体,针对多种蛋白质靶标,包括细胞骨架蛋白、酶、受体等。
信号通路抗体,用于研究 MAPK、PI3K/AKT、Wnt 等信号通路。
癌症研究抗体,针对肿瘤标志物(如 EGFR、HER2、p53)和癌症相关蛋白。
神经科学抗体,用于研究神经元标记物(如 GFAP、NeuN)和神经递质受体。
干细胞研究抗体,针对干细胞标记物(如 Oct4、Nanog、Sox2)。
(2)二抗(Secondary Antibodies)
偶联二抗,提供 HRP、荧光染料(如 FITC、Cy3、Cy5)和生物素偶联的二抗。
种属特异性二抗,针对小鼠、兔、大鼠、山羊等种属的一抗。
(3)免疫检测试剂
ELISA 试剂盒,用于定量检测特定蛋白质或生物标志物。
Western Blot 试剂,提供高灵敏度的检测试剂,如 ECL 底物和封闭缓冲液。
免疫组化(IHC)试剂,用于组织切片中靶标蛋白的定位和检测。
(4)定制抗体服务
多克隆抗体开发,根据客户提供的抗原开发定制多克隆抗体。
单克隆抗体开发,提供杂交瘤技术和单克隆抗体制备服务。
抗体标记和纯化,提供抗体偶联(如荧光标记、生物素标记)和纯化服务。

艾美捷科技代理BBI Solutions品牌诊断原料。
BBI Solutions的产品范围广泛,包括人的抗原、抗体、血清、血浆和临床化学酶等优质原料,还生产世界知名的ELISA试剂盒、生物传感器的标签、黄金纳米粒子和葡萄糖氧化酶等。BBI Solutions提供一系列专业的服务,包括抗体开发、抗体制造、抗原定制、金共轭化等。其独特的抗体开发、侧向流动试验开发和制造服务组合,能够支持客户从概念到商业化的全过程。BBI Solutions拥有专业的研究团队和完善的生产和质控流程,确保了公司产品的高品质。其提供的技术支持涵盖了产品的应用验证、配对使用抗体的推荐等方面,为客户提供了全方位的技术保障。BBI Solutions公司提供试剂专用酶:辣根过氧化物酶、谷氨酸脱氢酶、碱性磷酸酶、尿素酶、胆固醇酯酶,聚链霉亲和素,人源蛋白,单克隆抗体,金纳米颗粒等。
<<< " data-original="http://pharna.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理BBI Solutions品牌诊断原料"> 艾美捷科技代理BBI Solutions品牌诊断原料
<艾美捷科技代理Innovative Biochips品牌全系列产品
Innovative Biochips是休斯顿德克萨斯医学中心(TMC)的衍生公司,专注于开发先进的微流控技术,以尖端的灵敏度和高通量解决传统生物技术面临的难题。科研团队和工程师在为各类生物和生物医学应用开发新型微流体技术方面积累了的经验。通过不断创新和优化技术,Innovative Biochips为生命科学研究提供了更精准的工具,推动生物医学领域的进步。主要产品包括单细胞克隆分析、单细胞成像和配对、球状细胞培养等。
▍Innovative Biochips公司产品线
● 单细胞PCR与测序技术:本系列产品融合标准设备制式与创新微流控设计,提供多种简易、快速、经济的单细胞分离方案:实现单细胞向超微量液体环境的高效转移;完美适配单细胞裂解、PCR及测序等遗传分析流程。
● 单细胞克隆:在重组蛋白生产、基因功能研究与药物筛选中应用广泛。1CellPlate®-96孔超微量微流控板采用标准96孔板规格,结合独特的"孔中孔"微流控设计,为癌细胞、杂交瘤细胞、CHO细胞、CRISPR编辑细胞及干细胞等稳定细胞株开发,提供前所未有的简易单细胞分离方案。
● 单细胞检测:1CellPlate®-Assay 超低体积 96 孔微流控微孔板结合了超小孔和微流控网络,满足了单细胞细胞因子检测的需求。单细胞分泌的细胞因子可被收集并通过质谱进行深度分析。此外,具有显著高细胞因子分泌量的单细胞,也能通过常规移液器轻松回收,用于包括克隆或 PCR 测序在内的下游分析。
● 自动化寿命检测:自动解剖芯片 (AD-Chip) 结合延时显微技术,可在 3 天内对 20 种不同菌株的逾万个单酵母细胞进行自动化全寿命追踪。该芯片能够在整个衰老过程中对单细胞进行高分辨率荧光成像。

▍Innovative Biochips产品列表
| 品名 | 货号 | 目录 | 规格 |
| 1CellDish-60mm | H2-SCD-5PK | Single-Cell Cloning and Analysis, Single-Cell Devices, Single-Cell PCR & Sequencing | 5 Petri Dishes |
| 1CellDish-Glass Bottom | H6-SGB-5PK | Glass Bottom Devices, Single-Cell Cloning and Analysis, Single-Cell Devices, Single-Cell PCR & Sequencing | 5 Petri Dishes |
| 1CellPlate-mini | P2-SCPM-5PK | Single-Cell Cloning and Analysis, Single-Cell Devices, Single-Cell PCR & Sequencing | 5 Plates |
| 1CellPlate-Glass Bottom | P2-SCPM-5PK | Single-Cell Cloning and Analysis, Single-Cell Devices, Single-Cell PCR & Sequencing | 5 Plates |
| 1CellPlate-96well | P2-SCPM-5PK | Single-Cell Cloning and Analysis, Single-Cell Devices, Single-Cell PCR & Sequencing | 5 Plates |
| 1CellPlate-96Well Low Evaporation | P2-SCPM-5PK | Single-Cell Cloning and Analysis, Single-Cell Devices, Single-Cell PCR & Sequencing | 5 Plates |
| 1CellAssay-Chamber Slide | H7-SCS-5PK | Glass Bottom Devices, Single-Cell Cloning and Analysis | 5 Chamber Slides |
| 1CellAssay Lysis Kit | K1-SCLS-KIT | Single-Cell Cloning and Analysis, Single-Cell Kits, Single-Cell PCR & Sequencing | - |
| 1CellArray-Glass Bottom | H5-GBD-5PK | Glass Bottom Devices, Single-Cell Devices, Single-Cell Imaging and Pairing | 5 Petri Dishes |
| Cell Pairing Plate | P6-CPP-5PK | Cell Pairing Devices, Single-Cell Imaging and Pairing | 5 Plates |
| Gridded Polystyrene Dish for Super Resolution Imaging-70um Wells | H11-SPD-10PK | Single-Cell Imaging and Pairing | 10 Petri Dishes |
| Gridded Polystyrene Dish for Super Resolution Imaging-50um Wells | H12-SPD-10PK | Single-Cell Imaging and Pairing | 10 Petri Dishes |
| Gridded Polystyrene Dish for Super Resolution Imaging-30um Wells | H13-SPD-10PK | Single-Cell Imaging and Pairing | 10 Petri Dishes |
| PicoWell Dish-72K Wells | H8-PWD-10PK | Single-Cell Devices, Spheroid Cell Culture | 10 Petri Dishes |
| PicoWell Dish-160K Wells | H9-PWD-10PK | Single-Cell Devices, Spheroid Cell Culture | 10 Petri Dishes |
| PicoWell Dish-300K Wells | H10-PWD-10PK | Single-Cell Devices, Spheroid Cell Culture | 10 Petri Dishes |
| 1CellAssay 3D Culture Kit | K2-SCTD-KIT | Single-Cell Culture, Single-Cell Kits, Spheroid Cell Culture | - |
| Million Microwell Device | H4-MMD-5PK | High-Throughput RNA-Sequencing, Single-Cell Devices, Single-Cell PCR & Sequencing | 5 MMDs |
| PicoWells In 6-Well Plate | H8-PWP-5PK | Glass Bottom Devices, High-Throughput RNA-Sequencing | 5 Plates |
| PicoWells In Chamber Slide | H9-PCS-5PK | Glass Bottom Devices, High-Throughput RNA-Sequencing | 5 Chamber Slides |
| Hole Array-1536 | S1-SHA-1536-10PK | High-Density Cell Culture and Imaging, Standard Hole Array | 10 Plates |
| Hole Array-384 | S2-SHA-384-10PK | High-Density Cell Culture and Imaging, Standard Hole Array | 10 Plates |
| Hole Array-6well | S3-SHA-900-10PK | High-Density Cell Culture and Imaging, Standard Hole Array | 10 Plates |
| Hole Array-60mm | S4-SHA-350-10PK | High-Density Cell Culture and Imaging, Standard Hole Array | 10 Petri Dishes |
| Hole Array-Glass Bottom | S5-SHA-75-10PK | High-Density Cell Culture and Imaging, Standard Hole Array | 10 Petri Dishes |
| Hole Array-Slide | S6-SHA-240-10PK | High-Density Cell Culture and Imaging, Standard Hole Array | 10 Slides |
| Hole Array-Coverslip | S7-SHA-240-10PK | High-Density Cell Culture and Imaging, Standard Hole Array | 10 Coverslips |
| Hole Array-Chamber | S8-SHA-160-12PK | High-Density Cell Culture and Imaging, Standard Hole Array | 12 Chamber Slides |
| Automated Dissection Chip | A1-AD-5PK-1 | Yeast Aging Assays | 5 Chips |
| Automated Dissection Screening Chip | A3-ADS-5PK | Yeast Aging Assays | 5 Chips |

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://pharna.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
<艾美捷科技代理VIDIA品牌全系列产品
VIDIA Ltd.是一家捷克私营生物技术公司,创立于1991年,是体外诊断试剂(IVD)生产商,产品应用于人类医学诊断和环境监测领域。自2003年起,公司已通过ISO 9001和ISO 13485认证。所有IVD产品均获得CE认证。其产品设计具有高稳定性和长保质期,且易于使用。

▍VIDIA公司产品线
● ELISA-VIDITEST™ 免疫酶联检测试剂盒:基于酶联免疫吸附法,具有抗体定量/半定量/定性分析、鞘内抗体合成测定以及抗体亲和力评估的检测功能。
● MONO-VIDITEST™ 单次检测盒:基于间接ELISA方法,用于测定样品中特异性抗体的含量。这些试剂盒旨在对血清、血浆、脑脊液和滑膜液样本中的 IgA、IgM 和 IgG 类抗体进行定量/半定量评估。
● LIA-VIDITEST:基于硝酸纤维素膜条的酶联线性免疫印迹法,单次运行即可并行检测多个样本的 IgM 和 IgG 抗体,经验证适用于全自动或半自动的 RoboBlot、BeeBlot、B20 分析仪。
● RAPID-VIDITEST 快速检测试剂盒:诊断型快速色谱免疫分析法,操作简便,结果易判读,可定性检测多种病毒、细菌、寄生虫的抗原。
● IF-VIDITEST:应用于多种感染的血清学诊断,具有高灵敏度与高特异性,操作流程简便的特点。
▍VIDIA部分产品列表
| 品名 | 规格 | 货号 |
| ELISA-VIDITEST anti-complement factor H | 48 wells quantitative | ODZ-166 |
| ELISA-VIDITEST EDUCO Diagnostic | 96 wells 6 doublestrips | ODZ-191 |
| CMV - CI combi r.t.u. | 1 ml | ODZ-264 |
| VZV - CI combi r.t.u. | 1 ml | ODZ-289 |
| HSV-1 - CI nativ r.t.u. | 1 ml | ODZ-314 |
| HSV-2 - CI nativ r.t.u. | 1 ml | ODZ-315 |
| CMV - CI nativ conc. | 0,5 mg | ODZ-319/05 |
| VZV - CI nativ conc. | 0,1 mg | ODZ-320 |
| HSV-1 - CI nativ conc. | 0,1 mg | ODZ-321 |
| HSV-2 - CI nativ conc. | 0,1 mg | ODZ-322 |
| Control - CI r.t.u. (pro CMV, VZV) | 1 ml | ODZ-365 |
| Control - CI r.t.u. (pro HSV-1, HSV-2) | 1 ml | ODZ-366 |
| ELISA-VIDITEST Bisphenol A | 96 wells quantitative | ODZ-041 |
| ELISA-VIDITEST Microcystin-LR | 96 wells quantitative | ODZ-165 |
| ELISA-VIDITEST pNF-H (Neurofilament-H) | 96 wells quantitative | ODZ-437 |
| ELISA-VIDITEST anti-HSV1+2 IgG | 96 wells semiquantitative | ODZ-169 |
| ELISA-VIDITEST anti-HSV1+2 IgM | 96 wells semiquantitative | ODZ-234 |
| ELISA-VIDITEST anti-HSV1+2 IgA | 96 wells semiquantitative | ODZ-283 |
| MONO-VIDITEST anti-HSV IgG | 12 tests | KZ-140-12 |
| MONO-VIDITEST anti-HSV IgM | 12 tests | KZ-141-12 |
| ELISA-VIDITEST anti-EBNA-1 EBV IgG, doublestrip | 96 wells semiquantitative | ODZ-015 |
| ELISA-VIDITEST anti-EBNA-1 EBV IgG | 96 wells semiquantitative | ODZ-001 |
| ELISA-VIDITEST anti-EBNA-1 EBV IgM | 96 wells semiquantitative | ODZ-002 |
| ELISA-VIDITEST anti-VCA EBV IgG | 96 wells semiquantitative | ODZ-265 |
| ELISA-VIDITEST anti-VCA EBV IgG (CSF) | 96 wells quantitative | ODZ-084 |
| ELISA-VIDITEST anti-VCA EBV IgG and IgG avidity | 96 wells semiquantitative | ODZ-175 |
| ELISA-VIDITEST anti-VCA EBV IgM | 96 wells semiquantitative | ODZ-005 |
| ELISA-VIDITEST anti-VCA EBV IgA | 96 wells semiquantitative | ODZ-096 |
| ELISA-VIDITEST anti-EA (D) EBV IgG | 96 wells semiquantitative | ODZ-006 |
| ELISA-VIDITEST anti-EA (D) EBV IgM | 96 wells semiquantitative | ODZ-007 |
| ELISA-VIDITEST anti-EA (D) EBV IgA | 96 wells semiquantitative | ODZ-254 |
| MONO-VIDITEST anti-VCA EBV IgG | 12 tests | KZ-100-12 |
| MONO-VIDITEST anti-VCA EBV IgM | 12 tests | KZ-101-12 |
| MONO-VIDITEST anti-VCA EBV IgA | 12 tests | KZ-102-12 |
| MONO-VIDITEST anti-VCA EBV IgG avidita | 12 tests | KZ-103-12 |
| MONO-VIDITEST anti-EBNA-1 EBV IgG | 12 tests | KZ-110-12 |
| MONO-VIDITEST anti-EBNA-1 EBV IgM | 12 tests | KZ-111-12 |
| ELISA-VIDITEST anti-CMV IgG (CSF) | 96 wells quantitative | ODZ-102 |
| ELISA-VIDITEST anti-CMV IgG and IgG avidity | 96 wells semiquantitative | ODZ-177 |
| ELISA-VIDITEST anti-CMV IgM | 96 wells semiquantitative | ODZ-402 |
| ELISA-VIDITEST anti-CMV IgA | 96 wells semiquantitative | ODZ-164 |
| ELISA-VIDITEST anti-VZV IgG | 96 wells semiquantitative | ODZ-168 |
| ELISA-VIDITEST anti-VZV IgG (CSF) | 96 wells quantitative | ODZ-087 |
| ELISA-VIDITEST anti-VZV IgG and IgG avidity | 96 wells semiquantitative | ODZ-233 |
| ELISA-VIDITEST anti-VZV IgM | 96 wells semiquantitative | ODZ-197 |
| ELISA-VIDITEST anti-VZV IgA | 96 wells semiquantitative | ODZ-284 |
| MONO-VIDITEST anti-EA(D) EBV IgG | 12 tests | KZ-120-12 |
| MONO-VIDITEST anti-EA(D) EBV IgM | 12 tests | KZ-121-12 |
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771997407
传真:18771997407
邮箱:sales@amyjet.com
0.1878